What LDL measures and why it's incomplete
Low-density lipoprotein cholesterol (LDL-C) is a measure of the quantity of cholesterol carried within LDL particles in the bloodstream. It is the most widely ordered lipid marker in clinical practice and a well-established risk factor for atherosclerotic cardiovascular disease.
The limitation of LDL-C as a risk marker: it measures the cholesterol content of LDL particles, not the number of those particles. Two patients can have identical LDL-C of 120 mg/dL but carry that cholesterol in very different numbers of particles. One patient may carry it in 1,200 large, buoyant LDL particles; another may carry it in 1,800 smaller, denser LDL particles. The second patient has substantially higher cardiovascular risk — more particles means more chances for plaque-initiating penetration into the arterial wall — but their LDL-C appears identical.
This discordance between LDL-C and LDL particle number is most common in patients with insulin resistance, metabolic syndrome, elevated triglycerides, and low HDL — precisely the metabolic pattern prevalent in Indian adults.
What ApoB measures
Apolipoprotein B (ApoB) is a structural protein. Every atherogenic lipoprotein particle — each LDL, VLDL, IDL, and Lp(a) particle — carries exactly one ApoB molecule on its surface. No exceptions.
This means ApoB is a direct count of the total number of atherogenic particles in circulation, regardless of how much cholesterol each particle carries.
A meta-analysis by Sniderman et al. covering data from over 230,000 participants found that ApoB was more strongly associated with myocardial infarction risk than LDL-C across all populations studied. The superiority of ApoB as a risk predictor is most marked in patients with high triglycerides and low HDL — the metabolic pattern common in Indian adults.
The discordance that matters clinically
The patients for whom ApoB matters most are those in whom LDL-C underestimates risk — where the two measures are discordant:
Patients with insulin resistance and high triglycerides. Insulin resistance promotes the production of small dense LDL particles. These particles carry less cholesterol per particle than large buoyant LDL, so LDL-C may appear normal while ApoB (particle count) is elevated. A patient with LDL-C of 110 mg/dL, triglycerides of 200 mg/dL, and HDL of 35 mg/dL may have an ApoB of 120 mg/dL — indicating substantially higher atherogenic particle burden than LDL-C suggests.
Patients on statin therapy. Statins reduce LDL-C effectively. They also reduce ApoB, but not always proportionally. A patient whose LDL-C has fallen to target on a statin but whose ApoB remains elevated may not be adequately treated. Monitoring ApoB provides a more accurate assessment of residual risk.
Indian patients specifically. The "thin-fat Indian" phenomenon — normal or near-normal BMI with elevated visceral fat and insulin resistance — creates the lipid pattern of high triglycerides, low HDL, and small dense LDL that is most poorly captured by LDL-C alone.
How to interpret an ApoB result
ApoB is measured in mg/dL (or g/L in some laboratories). Reference values differ between guidelines:
- The 2018 AHA/ACC cholesterol guidelines propose ApoB < 90 mg/dL as optimal for primary prevention
- For patients with established cardiovascular disease or very high risk, < 70 mg/dL is the target in most guidelines
- The European guidelines are slightly more stringent
The key is not the absolute cut-off but the comparison to cardiovascular risk: a patient at high baseline cardiovascular risk (hypertension, diabetes, smoking, family history) with ApoB of 110 mg/dL carries more risk than a patient at low baseline risk with the same value.
ApoB in the Indian context
India's cardiovascular disease burden is disproportionate to its BMI profile — Indians develop atherosclerosis and its consequences at younger ages and lower body weights than Western populations. The metabolic syndrome phenotype most common in India (central obesity with normal BMI, high triglycerides, low HDL, and insulin resistance) is the phenotype most strongly associated with ApoB-LDL-C discordance.
Including ApoB in a cardiovascular risk assessment for Indian adults — particularly those with metabolic risk factors — is not an extravagance. It is the measurement that answers the question LDL-C cannot fully answer: how many atherogenic particles does this patient actually have in circulation?